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Abstract
Fragile X syndrome is the most frequent cause of inherited mental retardation. The phenotype in this syndrome is
quite variable and less conspicuous in younger patients, making clinical diagnosis difficult and thus making molecu-
lar diagnosis necessary. The use of clinical checklists in mentally retarded individuals can help selecting patients to
be given priority in the molecular investigation for the fragile-X mutation in the FMR1 gene. We evaluated two clinical
checklists in a sample of 200 Brazilian male patients with mental retardation. The highest scores in the two checklists
concentrated among the 19 males (9.5%) found to carry full mutations. Our results confirm the importance of frag-
ile-X checklists as a clinical tool in the study of mentally retarded patients.
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Introduction
Mental retardation is one of the most common human
disorders, affecting around 3% of the world population. It
becomes evident during the school years, when it manifests
as developmental delay (Toniolo, 2000). It has been long
recognized that there is an excess of males of about 30%
over females among mentally retarded individuals, and this
excess is in part explained by mutations in X-linked genes
(Ropers and Humel, 2005). Thus, a common situation in
clinical genetic centers is large number of mentally re-
tarded male patients with no chromosomal alteration or
other recognizable cause for their condition.
Fragile X syndrome is the most frequent cause of in-
herited mental retardation, with a prevalence of 1:4000 to
1:6000 for males and 1:8000 to 1:9000 for females
(Crawford et al., 2001). In almost all cases, the fragile X
syndrome results from a dynamic mutation, characterized
by an abnormal expansion of the CGG repeat at the 5’ un-
translated region (UTR) of the fragile-X mental retardation
gene (FMR1). This expansion, which is associated with the
methylation of the adjacent CpG island, leads to the ab-
sence of the FMRP protein (Pieretti et al., 1991) and, conse-
quently, fragile X syndrome. The discovery of the FMR1
mutation in 1991 allowed the development of reliable diag-
nostic methods (Fu et al., 1991; Oberlé et al., 1991). Two
approaches are generally used, Southern blot analysis and
the polymerase chain reaction (PCR). Southern blotting is
the golden standard method for laboratory diagnosis be-
cause it not only allows the accurate identification of the
full mutation and the premutation state but also reveals the
methylation status and can detect all size ranges of the mu-
tation. Southern blot analysis is, however, expensive and
time-consuming and PCR is cheaper and has a shorter turn-
around time, although the efficiency of PCR is inversely re-
lated to the number of CGG repeats and it is only accurate
in the sizing of alleles in the normal and premutation
ranges.
The fragile X phenotype is quite variable but its main
and most consistent clinical feature is mental retardation
but since physical and behavioral characteristics vary de-
pending on age and sex (Hagerman et al., 1991) clinical di-
agnosis is difficult and makes molecular diagnosis
necessary. Although mental retardation is a common disor-
der, providing fragile X molecular analysis to all patients
would not only be prohibitively costly but, in many cases,
unnecessary, a practical alternative being to select patients
with a high probability of being affected by fragile X syn-
drome for further molecular analysis. Several fragile-X
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checklists for identifying males who might be affected by
this syndrome have been published (Butler et al., 1991;
Hagerman, 1991; Laing et al., 1991; Arvio, 1997; De Vries,
1999; Limprasert, 2000; Maes, 2000). These checklists are
based on the most common characteristics of the syndrome.
According to Mandel and Biancalana (2004), the use of
checklists to select patients that are likely to have fragile X
syndrome may reduce by 60 to 80% the number of individ-
uals submitted to molecular evaluation, thus avoiding
waste and increasing the positive diagnosis rate.
During the research reported in this paper we used the
checklists published by Butler et al. (1991) and Laing et al.
(1991) and evaluated their selective power by comparing
the results of molecular diagnosis with the checklist scores
for 200 mentally retarded patients.
Material and Methods
Study group
In this study we enrolled 200 male Brazilian patients
between 3 and 36 years old (mean = 11.3 y) presenting
mental retardation and attending the Hospital São Paulo,
Brazil, as outpatients. All the males had normal karyotypes,
and males with known dysmorphic and metabolic syn-
dromes with mental retardation were not enrolled. The Re-
search Ethics Committee at UNIFESP approved this study
and informed consent was obtained from the patients’ par-
ents.
Checklist evaluation
The checklist proposed by Butler et al. (1991) con-
sists of 15 items: mental retardation, large ears, large testes,
hyperactivity, family history of mental retardation or au-
tism, short attention span, tactile defensiveness, hyper-
extensible finger joints, perseverative speech, hand-flap-
ping, hand biting, poor eye contact, Sydney palmar crease,
plantar crease and pale blue eyes.
Laing et al. (1991) proposed a clinical score based on
five items: family history of intellectual handicap, face
length, ear configuration, personality (lack of eye contact
followed by friendliness and verbosity with echolalic
speech patterns) and body habits (slim physique with tall
stature, rounded shoulders, hyperextensible finger joints,
lack of body hair or an obese physique with feminine distri-
bution of body fat and stria).
For both lists, each item received a score of 0 if never
present, 1 if present in the past or if questionable or border-
line or 2 if definitely present. The maximum score for an in-
dividual varies from 0 to 30 on Butler’s checklist and from
0 to 10 on Laing’s checklist, the scores being divided into
the intervals shown in Table 1. The same clinical geneticist
applied the checklists to all the males.
Molecular analysis
Genomic DNA was obtained from peripheral blood
leukocytes by the salting-out method described by Lahiri
and Nurnberger (1991), with modifications. DNA samples
were analyzed using the PCR according to Haddad et al.
(1996). In this method genomic DNA is amplified by one
forward and two reverse primers in two combinations, one
pair of primers flanking the trinucleotide repeat region am-
plifies a fragment containing the variable CGG region
while the other pair of primers amplifies a smaller 223 bp
fragment of the CGG region used as an internal control. The
conditions were established in such a manner that full mu-
tations would fail to amplify the variable region, i.e. males
with the normal gene showed two amplified bands while
those with the fully mutated gene showed only the control
band. The PCR products were separated by electrophoresis
on a proprietary acrylamide gel (GeneGel Excel, GE Health
Care®, Sweeden) and silver-stained according to Santos et
al. (1993). Three reactions were performed for each patient.
All positive results for FMR1 mutations were validated by
Southern blot analysis according to Mingroni-Netto et al.
(1996).
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Table 1 - Accumulated score frequency distribution for mentally retarded males (n = 200) who showed a normal (181) or mutated (19) fragile X mental
retardation gene (FMR1) and had been scored for fragile X syndrome according to the checklists of Butler et al. (1991) and Laing et al. (1991). For each
score interval the difference between accumulated percentage (Ac. %) values was calculated as the Ac. % for males with a normal FMR1 gene minus the
Ac. % for males with a mutated FMR1 gene. Statistical analysis showed significantly higher Butler (χ2 = 33.28, p < 0.001) and Laing (χ2 = 14.68,
p < 0.001) scores for males with the mutant gene compared with males with the normal gene.
Butler score intervals Laing score intervals
Parameters 2 to 5 6 to 9 10 to 13 14 to 17 18 to 21 22 to 25 26 to 29 2 to 4 5 to 7 8 to 10
Normal FMR1 gene (n = 181 males)
Accumulated number of males 0 8 32 109 164 180 181 23 120 181
Accumulated % of males 0 4.42 17.68 60.22 90.61 99.45 100 12.71 66.30 100
Mutated FMR1 gene (n = 19 males)
Accumulated number of males 0 0 1 3 4 13 19 0 4 19
Accumulated % of males 0 0 5.26 15.79 21.05 68.42 100 0 21.05 100
Difference between accumulated % values 0 4.42 12.42 44.43 69.56 31.03 0 12.71 45.25 0
Statistical analysis
The males were distributed into two groups according
to their molecular results, as negative for the full mutation
(normal FMR1) or positive for the full FMR1 mutation
(mutant FMR1). Clinical scores of the two groups were
compared using the Kolmogorov-Smirnov test (Siegel and
Castellan, 2006).
Results
The PCR showed that 181 (90.5%) of the males were
carrying a normal FMR1 gene while 19 (9.5%) had a fully
mutated FMR1 gene, confirmed by Southern blotting. No
premutation was detected.
Scores varied from 6 to 28 on the Butler checklist and
from 2 to 10 on the Laing checklist, the distribution of
males with the normal FMR1 gene and those with the full
FMR1 mutation according to their Butler or Laing scores
being presented in Table 1. For males with normal FMR1
genes the Butler score ranged from 6 to 26 and the Laing
score from 2 to 10, while for males with a mutated FMR1
gene (i.e. with fragile X syndrome) the Butler score ranged
from 12 to 28 and the Laing score from 5 to 10. Butler and
Laing scores were significantly higher (χ2 = 33.28,
p < 0.001) and (χ2 = 14.68, p < 0.001), respectively, for
males with fragile X syndrome than for those without frag-
ile X syndrome. The largest differences between accumu-
lated frequencies of mutated and normal males were at the
18 to 21 Butler score interval (Dmax = 0.69555), and at the
5 to 7 Laing score interval (Dmax = 0.4525), which can be
considered as the cutoff points above which the presence of
fragile X syndrome is probable (Table 1).
Discussion
Because of the high frequency of fragile X syndrome
among mentally retarded males, checklists have been pro-
posed to help identify males who should be submitted to
laboratory tests. We used the Butler and the Laing check-
lists to study 200 mentally retarded male patients and found
that scores were significantly higher for males with the full
FMR1 mutation than for males with a normal FMR1 gene,
confirming the utility of checklists for screening for Fragile
X syndrome.
There are no cutoff points in either the Butler or the
Laing checklist, so to make these checklists more useful
and simpler to apply we determined a cutoff point based on
the molecular results for our sample of males with normal
or mutated FMR1 genes. Of the 200 males tested, the mo-
lecular techniques identified a total of 19 males (9.5%) car-
rying the full FMR1 gene mutation and our Butler checklist
results showed that if we had used molecular techniques to
investigate only males with a score higher than, or equal to,
the Butler score (18) with the greatest difference between
the number of males with a normal gene and the number of
males with a mutated gene we would have had to perform
molecular tests not on 200 males but on only 88 males, 16
of which (18.2% of 88) would have been positive for fragile
X syndrome. Of the 122 males (61% of the total) classified
with a Butler score lower than 18 only 3 (2.5% of 122) had a
fully mutated gene, so if we had used a cutoff score of be-
low 18 we would have had to assess more males to detect a
similar number of males with a mutated gene as would have
been the case if we had used a cutoff point of 18 or higher.
In fact, we would have had to test 192 of the males (96% of
the total) to avoid missing any a mutated gene, i.e. almost
the all the males in the study. Of course, in actuality, all the
males enrolled in this study were tested using molecular
techniques, but our data shows that the judicious use of ap-
propriate Butler scale cutoff points can result in effective
screening and reduce the number of molecular investiga-
tions needed
There were 177 males (88.5% of the total) who had a
Laing score of 5 or higher, for which we found the highest
difference between the number of males with a normal gene
and the number of males with a mutated gene. This group of
177 males contained all 19 males (10.73% of 177) which
molecular techniques had shown to have a fully mutated
FMR1 gene The 177 males with the highest Laing scores
was over twice the 88 with a Butler score of 18 or over, in-
dicating that the Butler checklist would result in a smaller
number of candidates for molecular evaluation and has
better applicability in clinical management.
Some of the males who carried a full FMR1 gene mu-
tation presented intermediate or low scores on the check-
lists. For the younger males this could have been because
the phenotype tends to become more evident with age, usu-
ally after puberty, but this is not the only reason since one
male was 18 years old but did not present any syndromic
features.
In some of the males with severe mental retardation,
characteristics related to speech were difficult to evaluate
since they did not speak and this was important for evalua-
tion using the Laing checklist because one of the five char-
acteristics evaluated is personality and this is related to
speech. This fact could have caused the low Laing scores
found in patients with positive molecular results.
The Butler checklist considers 15 characteristics,
some of which, such as pale blue eyes, were uncommon in
our population. Pale blue eyes is not a feature of fragile X
syndrome but was associated to the syndrome because the
early patients diagnosed were of European origin. This fact
points to the need for developing a checklist based on char-
acteristics which are more common in Brazilian patients.
In our sample, most (15 out of 19) of the males identi-
fied with fragile X syndrome had a family history of mental
retardation and there was a significant association
(p < 0.001) between these two factors. Neri et al. (1994) re-
ported that one third of patients with familial X-linked
mental retardation have fragile X syndrome. In our sample
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15 of the 60 males (25%) with familial mental retardation
presented the fragile X syndrome.
Given the high frequency of mentally retarded males
in the general population, the implementation of checklist
screening methods can help reduce the number of patients
selected for molecular analysis, with a higher percentage of
positive results and no significant loss of false-negative re-
sults.
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